Chemistry:Levormeloxifene

Short description: Chemical compound

Levormeloxifene

Clinical data
Other names	Levomeloxifene; 6720-CDRI; NNC-460020
Identifiers
IUPAC name 1-(2-[4-[(3R,4R)-7-Methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2H-chromen-4-yl]phenoxy]ethyl)pyrrolidine
CAS Number	78994-23-7 N
PubChem CID	35805
ChemSpider	32935 Y
UNII	9512UKZ352
ChEMBL	ChEMBL301327 Y
Chemical and physical data
Formula	C30H35NO3
Molar mass	457.614 g·mol−1
3D model (JSmol)	Interactive image
SMILES O(c1ccc(cc1)[C@@H]3c4c(OC([C@H]3c2ccccc2)(C)C)cc(OC)cc4)CCN5CCCC5
InChI InChI=1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1 Y Key:XZEUAXYWNKYKPL-WDYNHAJCSA-N Y
NY (what is this?)  (verify)

Levormeloxifene (INN; developmental code names 6720-CDRI, NNC-460020) is a selective estrogen receptor modulator (SERM) which was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss but did not complete development and hence was never marketed. The development was stopped because of a high incidence of gynecological side effects during clinical trials. Levormeloxifene is the levorotatory enantiomer of ormeloxifene, which, in contrast, has been marketed, though rather as a hormonal contraceptive.

See also

• List of selective estrogen receptor modulators

External links

• Levormeloxifene - AdisInsight